SPOTLIGHT: Allergan to pay $370M for Esprit Pharma


Allergan has inked a deal to buy privately held Esprit Pharma, which specializes in genitourinary treatments, for $370 million. Esprit currently markets Sanctura, a remedy for overactive bladder, and has applied for FDA approval for an extended release form of that drug. Release

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.